Drugs / ABBV-1042
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07222709 | Oct 2025 → May 2026 overdue | — | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-1042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07222709 ↗ |
| Route | Oral | “Participants will receive an oral dose of ABBV-1042 or placebo on day 1.” NCT07222709 ↗ |